

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-863]

**Importer of Controlled Substances  
Application: Alcami Carolinas Corporation**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Alcami Carolinas Corporation has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 9, 2021. Such persons may also file a written request for a hearing on the application on or before August 9, 2021.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on May 18, 2021, Alcami Carolinas Corporation, 1726 North 23rd Street, Wilmington, North Carolina 28405-1822, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Psilocybin .....	7437	I
Psilocyn .....	7438	I
Pentobarbital .....	2270	II
Thebaine .....	9333	II

The company plans to import the listed controlled substances in bulk for the manufacturing of capsules/tablets for Phase II clinical trials. The company plans to import derivatives of Thebaine that have been determined by DEA to be

captured under drug code (9333) Thebaine. No other activity for these drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

**William T. McDermott,**  
*Assistant Administrator.*

[FR Doc. 2021-14533 Filed 7-7-21; 8:45 am]

**BILLING CODE P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-862]

**Importer of Controlled Substances  
Application: Aspen API, Inc.**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Aspen API, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 9, 2021. Such persons may also file a written request for a hearing on the application on or before August 9, 2021.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on May 5, 2021, Aspen API, Inc., 2136 Wolf Road, Des Plaines,

Illinois 60018, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Remifentanyl .....	9739	II

The company plans to import the listed controlled substance as a bulk active pharmaceutical ingredient (API) for distribution to manufacturers of finished dosage prescription drugs. No other activity for these drug codes is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of the Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

**William T. McDermott,**  
*Assistant Administrator.*

[FR Doc. 2021-14530 Filed 7-7-21; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Parole Commission**

**Certification of Meeting Closure**

Pursuant to the Government in the Sunshine Act (Pub. L. 94-409) [5 U.S.C. Section 552b]

I, Helen H. Krapels, General Counsel of the United States Parole Commission, certify, pursuant to 5 U.S.C. Section 552b(f)(1):

In my opinion a meeting of the Commission to be held on Tuesday, July 13, 2021 at approximately 2:00 p.m., at the U.S. Parole Commission, 90 K Street NE, Washington, DC 20530, could be closed to the public in the event that a majority of the Commissioners present vote to close said meeting at the beginning thereof, with the vote properly recorded.

The exemptions of the Government in the Sunshine Act that may allow closing the meeting to the public 5 U.S.C. 552b(c)(10) and (d)(4) (for applicable Parole Commission regulations see 28 CFR 16.203(a)(10), 16.205(a) and 16.205(b)(1)). In addition, the following laws and regulations may apply to exempt disclosure to the public portions of the subject matter of this meeting: 5 U.S.C. 552b(c)(3), (6) and (7) and 28 CFR 16.203(a)(3), (6), and (7).

In witness whereof, I have signed this document (and affixed the seal of the